C72YYZZ
Tomographic (Tomo) Nuclear Medicine Imaging Lymphatic and Hematologic System to None with None, Other Radionuclide Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 2 Tomographic (Tomo) Nuclear Medicine Imaging |
| Body Part | Y Lymphatic and Hematologic System |
| Approach | Y Other Radionuclide |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of radioactive materials into the body for three dimensional display of images developed from the capture of radioactive emissions
Procedure Overview
Tomographic nuclear medicine imaging of the lymphatic and hematologic system produces three-dimensional pictures built from radioactive emissions captured as a detector rotates around the patient, offering more spatial detail than a flat, single-plane scan. Common applications include imaging the spleen to evaluate its size, function, or the presence of accessory spleen tissue, and bone marrow scans that assess how well marrow is producing blood cells across the skeleton.
These studies are typically ordered when a flat image would not give enough detail to answer the clinical question, such as when a physician needs to see the exact three-dimensional distribution of functioning marrow, or precisely localize splenic tissue before a planned surgery. The added detail comes from the same rotational data-collection principle used in other tomographic nuclear medicine studies, just applied to lymphatic and blood-forming tissue rather than another organ system.
Anatomy & Axis Detail
Lymphatic and Hematologic System
Tomographic imaging coded to the lymphatic and hematologic system generally, rather than to spleen or another discrete structure, applies to SPECT or SPECT/CT studies that characterize tracer uptake across multiple hematopoietic or lymphatic sites in a single acquisition, such as combined marrow and splenic imaging or a multi-station lymphatic survey performed for staging or occult disease localization. This designation is reserved for studies whose findings are not attributable to one named organ or regional lymphatic bed, and it allows cross-sectional evaluation of activity patterns that a planar acquisition alone cannot resolve, including depth localization and separation of overlapping structures. Clinical indications include diffuse marrow disorders, systemic lymphoproliferative processes, or search for ectopic hematopoietic tissue. As with the corresponding planar code, documentation must support that the study genuinely spans the system rather than a single identifiable body part.
Radionuclide: Other Radionuclide
Other Radionuclide is used when a nuclear medicine study employs a radioactive tracer that does not correspond to one of the specifically named isotope values in this axis, such as an uncommon or newer radiopharmaceutical. It functions as a catch-all so the procedure can still be coded precisely by section and root operation even when the exact tracer lacks its own dedicated code value.
Coding & Documentation
Documentation needs to establish that the images were reconstructed from a rotational, three-dimensional acquisition rather than a series of flat views, since this is the feature that separates this root operation from planar imaging of the same body system. The specific organ or tissue studied, such as spleen versus bone marrow, should be clearly identified because it drives body part selection. A recurring error is coding a tomographic marrow or spleen study as a general "blood" study without pinning down the actual anatomic target documented in the radiology report.
Commonly Confused With
The closest source of confusion is Planar Nuclear Medicine Imaging of the same body system; both use similar tracers and target the same organs, but the tomographic version is reserved for studies that specifically reconstruct a three-dimensional volume rather than capturing single flat views. It can also be confused with PET imaging of other body systems when FDG is used for lymphoma staging, but lymphoma PET studies are typically coded under a whole-body or different body-system category rather than this lymphatic and hematologic tomographic family, depending on what the report actually documents.